S. Ken Tanaka
Nessuna posizione attualmente
Profilo
Dr. S.
K.
Tanaka is Vice President-Research & Development at Paratek Pharmaceuticals, Inc.
Dr. Tanaka was previously employed as Vice President-Research & Development by Paratek Pharmaceuticals, Inc. /Old/, Senior Director by PathoGenesis Corp, Project Leader by Abbott Laboratories, a Principal by SCHWARZ PHARMA, Inc., and Scientist by E.R.
Squibb & Sons LLC.
He received his undergraduate degree from the University of Washington and a doctorate degree from Northwestern University.
Precedenti posizioni note di S. Ken Tanaka
| Società | Posizione | Fine |
|---|---|---|
| PARATEK PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | - |
| E. R. Squibb & Sons LLC | Direttore Tecnico/Scientifico/R&S | - |
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Corporate Officer/Principal | - |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Direttore/Membro del Consiglio | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Formazione di S. Ken Tanaka
| Northwestern University | Doctorate Degree |
| University of Washington | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
PathoGenesis Corp
PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |
Schwarz Pharma, Inc.
Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Health Technology |
| E. R. Squibb & Sons LLC |
- Borsa valori
- Insiders
- S. Ken Tanaka
